1. Scrip
  2. >>Business
  3. >>Legal & IP

Never Give Up: Amarin Will Appeal Latest Vascepa Patent Loss

Company Still Sees Profit Potential Even With US Generic Competitors

 
• By Mandy Jackson

A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.

Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.
Time is running out on Vascepa's US commercial opportunity

Amarin Corporation plc said it will make no immediate changes to its commercialization strategy for the purified fish oil product Vascepa (icosapent ethyl) after a three-judge panel of the US Court of Appeals for the Federal Circuit affirmed an earlier decision by the US District Court for the District of Nevada that invalidated patents related to Vascepa’s ability to lower high triglyceride levels. Amarin plans to seek an en banc review of the Federal Circuit’s 3 September decision by the full 12-member appellate court.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Business

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.